Inactive Instrument

Skystar Bio-Pharmaceutical Company Share Price Nasdaq

Equities

US8308843007

Biotechnology & Medical Research

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2012 3.36Cr 279.65Cr Sales 2013 4.25Cr 353.72Cr Capitalization 2.67Cr 222.32Cr
Net income 2012 60L 50Cr Net income 2013 1Cr 83Cr EV / Sales 2012 0.2 x
Net cash position 2012 56.09L 47Cr Net Debt 2013 24.98L 21Cr EV / Sales 2013 0.69 x
P/E ratio 2012
1.93 x
P/E ratio 2013
2.56 x
Employees -
Yield 2012 *
-
Yield 2013
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
Skystar Bio Pharmaceutical Company(NasdaqCM:SKBI) dropped from NASDAQ Composite Index CI
Skystar Bio Pharmaceutical Company Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Reiterates Earnings Guidance for the Fiscal 2014 CI
Skystar Bio Mulls Acquisitions CI
Skystar to Launch Probiotic Supplement for Dairy Cows by End of Fiscal 2014 CI
Skystar Bio Pharmaceutical Company Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Revenue Guidance for the 2014 CI
Skystar Bio Pharmaceutical Mulls Acquisitions CI
Skystar Launches Bovine Immunoglobulin G Kits in China CI
Skystar Bio Pharmaceutical Company Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Reaffirms Revenue Guidance for the Year 2014 CI
Skystar Bio-Pharmaceutical Company Announces Consolidated Earnings Results for the Year Ended December 31, 2013; Provides Revenue Guidance for the Year 2014 CI
Skystar Bio Mulls Acquisitions CI
Skystar Bio Pharmaceutical Company Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2013; Reiterates Earnings Guidance for the Fiscal 2013 CI
Skystar Bio Pharmaceutical Company Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2013; Reiterates Earnings Guidance of 2013 CI
Skystar Bio Pharmaceutical Company Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2013; Reiterates Revenue Guidance for the Year 2013 CI
Skystar Bio Pharmaceutical Company Reports Consolidated Earnings Results for the Year Ended December 31, 2012; Provides Earnings Guidance for the Fiscal 2013 CI
Skystar Bio Pharmaceutical Company Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2012; Revises Revenue Guidance for the Fiscal 2012 CI
More news
Members of the board TitleAgeSince
Director/Board Member 58 01/08/01
More insiders
Skystar Bio-Pharmaceutical Co., Ltd. is a manufacturer and distributor of veterinary medicines and healthcare products in China. The Company develops, manufactures, packages and distributes vaccines; Western medicines, Traditional Chinese Medicine (TCM); topicals, supplements, probiotics, and diagnostic kits and animal, animal nutrition supplements for poultry, livestock, marine aquaculture and domesticated pets within China. The Company operates four product lines: Probiotics, Veterinary Medicine, Veterinary Vaccines and Feed Additives. The Company provides a range of veterinary products serving regional micro-farms offering, such as Veterinary vaccines, including aquaculture, Veterinary medicines, Pro-biotic microorganisms and Animal feed additives. The Company's Veterinary drug products include Ivermectin Premix, Feizhu San, Tilmicosin Premix, Stimulated egg powder, Wulingsan, Yimu Shenghua San, Qingwen Baidu San and Spectinomycin Hydrochloride Injection.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW